Clinical Trial

Doravirine Dose Optimisation in Pregnancy

Study acronym: DoraDO
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A randomised, open label, controlled PK standard of care vs doravirine plus 2 nucleoside reverse transcriptase inhibitors backbone in pregnant women initiating combination antiretroviral therapy in the second trimester of pregnancy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-11-18; most recent amendment 2026-02-17.
Status change: Not Yet Recruiting → Recruiting 2023-11-10
Trial Details
NCT Number NCT05630638
Lead Sponsor University of Liverpool
Collaborators: Liverpool School of Tropical Medicine, Desmond Tutu Health Foundation
Conditions HIV
Enrollment 76 participants
Start Date 2023-10-10
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-19